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Targeted therapy has become increasingly important in the treatment of several solid tumour types such as colorectal cancer, breast cancer, renal cell carcinoma, head and neck cancer and lung cancer. The search for biologic characteristics determining the response to these agents is of great interest. This requires the development of new diagnostic tools and biomarkers. The selection of patients that are likely to benefit from targeted treatment will ultimately result in a more optimal patient outcome and a reduction of toxicity and costs. Several biomarkers have already been identified, such as overexpression of the gene encoding HER2 (ERBB2) as a predictor for the response to trastuzumab (a HER2 monoclonal antibody) in breast cancer
, and an activating KIT mutation in gastrointestinal stromal tumours mediating the response to imatinib [2] . [3] . Several [4] . Patients with advanced colorectal cancer and a tumour harbouring a KRAS codon 12 or 13 mutation are resistant to treatment with the EGFR monoclonal antibodies cetuximab [5] [6] [7] [8] [9] and panitumumab [10] . Therefore [6, 10, 13] but the assay has not been directly compared with sequencing. Although several different techniques to detect KRAS mutations are available [14] , international guidelines for the performance and interpretation of KRAS mutation analyses are still to be developed [15] (no. 11, 12, 14) . In two cases in which the assay was consistently positive while sequencing was negative and in two other cases in which only the first assay result was positive the ␦ Ct approximated 18, cut-off of 9) . The correlation between the ␦ Ct and tumour cell percentage for these two mutations is given in Fig. 2 . These four samples (marked as * in Fig. 2 [10] or with confirmation of all mutations by sequencing [6] . To learn more about the limitations and interlaboratory reproducibility of these analyses and considering the expected increase in the use of KRAS testing, a quality assurance program as proposed by the European Society of Pathology is warranted [15] . 
Involvement of the epidermal growth factor receptor (EGFR) signalling pathway has been identified in several cancer types. Binding of a ligand (EGF, transforming growth factor-␣, epiregulin, amphiregulin) to the receptor induces dimerization and autophosphorylation and subsequent stimulation of several intracellular signalling pathways such as the RAS/RAF/MAPK pathway and the phosphoinositide-3 kinase (PI3K) pathway. This ultimately results
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Fig. 2 ␦ Ct in relation to tumour cell percentage and true positive (᭺), false positive ( * ) and inclusive ( ) assay results with a fit line plus 95% CI for the individual values. (A) Results for KRAS c.35GϾA (p.Gly12Asp). For this alteration the ␦ Ct cut-off value as provided by the manufacturer of the kit was 8. (B) Results for KRAS c.38GϾA (p.Gly13Asp). For this alteration the
